Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been fully informed about the trial and have signed a consent form agreeing to take part.
- People who are covered by a health insurance plan.
- People who are 15 years old or older.
- People who have been diagnosed with Multiple Sclerosis (MS) according to recognised 2017 diagnostic guidelines.
- People who are already participating in a related study called the OFSEP-HD cohort (an linked study that this trial is connected to).
- People whose MS-related disability level falls within a specific range on a standard medical scale (scored 0 to 7.0 — confirm with trial site for what this means for a specific case).
- People who are taking MS medications or those who are not — both may be eligible.
- For one part of the trial (Work Package 3): people whose MS has been active during follow-up, meaning they have had a relapse, a worsening of disability, or new activity seen on a brain scan.
- For another part of the trial (Work Package 4): people whose MS has been stable, and who are being followed at either Nîmes or Nantes University Hospitals.
Who may not be able to join:
- People who have taken part in another interventional (hands-on) study in the past three months that could affect this trial's results.
- People who are currently in a waiting-out period required after a previous study.
- People who are under judicial protection (a legal status where a court oversees their affairs).
- People who are not able to be properly informed about the study, for example due to a language barrier or difficulty understanding the information.
- People who are pregnant or breastfeeding.
- People who are under 15 years old.
- People who are unable to answer questionnaires.
- People who have had a single episode that could suggest MS (called a Clinically Isolated Syndrome) but do not yet meet the full MS diagnosis criteria.
- People who have MS-like changes visible on a brain scan but have never had any symptoms (called Radiologically Isolated Syndrome).
- People who have a condition called Neuromyelitis Optica Spectrum Disorder, which is a separate condition from MS.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Eric Thouvenot, CHU Nimes
Phone: +33.(0)4.66.68.32.61
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease; GFAP level in patients with evolving disease compared to those with stable disease; Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease; GFAP level in patients with evolving disease compared to those with stable disease; Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease; GFAP level in patients with evolving disease compared to those with stable disease; Serum Neurofila...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.